Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals' stock (LGND) has experienced significant movement. The stock's 52-week range has been between $93.58 and $212.49. As of February 5, 2026, its market capitalization was $3.78 billion. Ligand reported $3.09 EPS for Q3 2025, beating analysts' estimates, and hosted its 2025 Investor Day, introducing 2026 guidance. News of a drug delay impacted the stock. There has been insider selling activity. Analysts have generally maintained a positive outlook, with a consensus rating of "Moderate Buy".

Information explicitly detailing the demand seasonality for Ligand Pharmaceuticals' products and services is not readily available. The company's revenue streams are primarily derived from royalties, licensing payments, and Captisol® sales, which may not exhibit strong seasonal patterns. The timing of royalty payments and milestone events from partners, as well as the timing of Captisol® customer orders, can influence revenue recognition.

Ligand Pharmaceuticals, Inc. (LGND) is a biopharmaceutical company focused on acquiring and developing royalty-generating assets within the healthcare sector. The company's business model revolves around providing financing and licensing its proprietary technologies, Captisol® and NITRICIL™, to support the clinical development of high-value medicines. Captisol® enhances the solubility, stability, and delivery of small-molecule drug candidates and is utilized in several FDA-approved products. NITRICIL™ facilitates tunable dosing, allowing for adjustable drug release profiles. Ligand's portfolio includes royalty rights to approximately 90 pharmaceutical products across diverse therapeutic areas.

Ligand Pharmaceuticals is headquartered in Jupiter, Florida, U.S., and has a global presence through strategic acquisitions and collaborations, extending across North America, Europe, and Asia.

Ligand Pharmaceuticals generally maintains a strong brand reputation, particularly within the financial and biotechnology communities, with positive analyst ratings. MarketBeat's MarketRank™ scored Ligand higher than 79% of companies in the medical sector. However, some concerns exist regarding the potential underperformance of royalty assets, challenges related to intellectual property durability, and uncertainty regarding the approval of clinical-stage royalty assets.

Ligand Pharmaceuticals Incorporated has significant institutional ownership, with 638 institutional owners and shareholders holding a total of 27,425,139 shares, accounting for approximately 88.24% of the company. Individual ownership is around 2.41%. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc.